[en] Hemoblot, a new immunological faecal occult blood test, produced by Gamma, Angleur, Belgium, was characterized and compared with another immunological test (HemeSelect, SmithKline Diagnostics, USA) and with a guaiac test (Hemoccult II, SmithKline Diagnostics). The analytical sensitivity of Hemoblot is 0.15 mg haemoglobin/g faeces and the test is specific for human haemoglobin. In addition, 135 symptomatic patients who had to undergo a colonoscopy were tested using the three tests. Two criteria were considered for the analysis: (1) the blood criterion: any pathology likely to cause colorectal or other bleeding; and (2) the precancerous-cancerous criterion: the pathology being either a colorectal polyp > 0.5 cm or a colorectal cancer. Considering both criteria, the sensitivity of Hemoblot was significantly higher than the sensitivity of Hemoccult: 38% and 23%, respectively, for the blood criterion; and 54% and 29% for the precancerous-cancerous criterion. Sensitivity and specificity did not differ statistically between Hemoblot and HemeSelect but Hemoblot was faster and simpler to perform. It could be widely used in mass screening.
Disciplines :
Oncology
Author, co-author :
Jeanson, Antoinette
Jamart, J.
Maisin, J. M.
Vanheuverzwyn, R.
Gohy, P.
Debongnie, J. C.
Rentier, Bernard ; Université de Liège - ULiège > Département de Microbiologie > Virologie fondamentale et Immunologie
Language :
English
Title :
Assessment of the new immunological test Hemoblot for detecting occult blood in faeces
Barrows GH, Burton RM, Jarrctt DD, Russell GG, Alfrod MD, Songster CI, (1478). Immunological detection of human blood in feces. AJCP 3: 342–6.
Crowley ML et al (1983). Sensitivity of guaiac-impregnated cards for the detection of colorectal neoplasia. J Clin Gastroenlerol 5: 127–30.
Frommer D (1992). Comparison of bowel cancer screening costs using immunological anil Hemoccult techniques for detecting faecal occult blood. In Faecal Occult Blood Tests(eds Young GP, Saito M); Smith-Kline Diagnostics Inc. San Jose, pp. 46–9.
Frommer DJ, Kapparis A, Brown MK (1988). Improved screening for colorectal cancer by immunological detection of occult blood. Br Med J 296: 1092–4.
Fujita M (1992). Colon cancer screening by immunochemical RPHA occult blood test. In Faecal Occult Blood Tests(eds Young GP, Saito H); Smith Kline Diagnostics Inc. San Jose, CA, pp. 82–9.
Fujita M, Sugiyama R, Kumanishi Y et al (1990) Evaluation of effectiveness of mass screening for colorectal cancer. World J Surg 14: 648–53.
Goldschmiedt M, Ahlquist DA, Wieand HS, McGill DB, Taylor WF, Ellefson RD (1988). Measurement of degraded fecal hemoglobin-heme to estimate gastrointestinal site of occult bleeding —appraisal of its clinical utility. Dig Dis Sci 5: 605–8.
Greegor DH (1967). Diagnosis of large-bowel cancer in the asymptomatic patients. JAMA 201: 943–5.
Hardcastle JD et al (1989). Randomized controlled trial of faecal occult blood screening for colorectal cancer: results for the first 107,349 subjects. Lancet i: 1160–4.
Kewenter J et al (1988). Screening and rescreening for colorectal cancer: a controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 62: 645–51.
Kronborg O, Fenger C, Sondergaard O, Pedersen KM, Olsen J (1987). Initial mass screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Funen in Denmark. Scand J Gastroenterol 22: 677–86.
Mandel JS et al (1993). Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328: 1365 -71.
Morris JB, Stellato TA, Guy BB, Gordon NH, Berger NA (1991). A critical analysis of the largest reported mass fecal occult blood screening program in the US. Am J Surg 161: 101–6.
Parkin DM, Laara E, Muir CS (1988). Estimates of the worldwide frequency of 16 major cancers in 1980. lnt J Cancer 41: 184–97.
St John DJB et al (1990). Most large and medium colorectal adenomas can be detected by immunochemical occult blood tests. Gastroenterology 5: A312.
Swase T (1992). The evaluation of an immunochemical occult blood test by reversed passive haemagglutination compared with Hemoccult II in screening for colorectal cancer. In Faecal Occult Blood Tests(eds Young GP, Saito H); SmithKline Diagnostics, Sanlose, CA, pp. 90–5.
Thomas D (1992). Colon cancer screening based on the radial immunodiffusion test, “Detectacol”. In Faecal Occult Blood Tests(eds Young GP, Saito H); Smith Kline Diagnostics, San Jose, CA, pp. 76–81.
Thomas WM, Pye G, Hardcastle JD, Walker AR (1992). Screening for colorectal carcinoma: an analysis of the sensitivity of Hemoccult. Br J Surg 79: 833–5.
Väänänen P, Tenhunen R (1988). Rapid immunochemical detection of fecal occult blood by use of a latex-agglutination test. ClinChem 9: 1763–6.
Voller A, Bidwell J, Bartlett A (1976). Microplate enzymes immunoassays for the immunodiagnosis of virus infections. In Manual of Clinical Immunology(eds Rose NR. Friedman H); American Society for Microbiology. Washington DC. p. 506.
Winawer SJ et al (1980). Progress report on controlled trial of fecal occult blood testing for the detection of colorectal neoplasia. Cancer 45: 2959–64.
Winawer SJ, John J St, Bond J et al (1990). Screening of average-risk individuals for colorectal cancer. Bull WHO 4: 505–13.
Young GP, St John DJB (1992). Faecal occult blood tests: choice, usage and clinical applications. Clin Biochem Rev 13: 161–7.
